Compare Boston Scientific Corporation (BSX) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Simon Property Group Inc — how do they compare? Boston Scientific Corporation trades at $43.48 (market cap $66.37B), while Simon Property Group Inc trades at $221.55 (market cap $71.76B). The key difference: Boston Scientific Corporation and Simon Property Group Inc are close in size by market cap, and Simon Property Group Inc pays a 3.98% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | SPG | |
|---|---|---|
Market Cap | $66.37B | $71.76B |
Sector | Health | Real Estate |
52-Week High | $108.14 | $227.56 |
52-Week Low | $42.63 | $159.93 |
Enterprise Value | $75.94B | $100.24B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
SPG trades at $219.49, up 0.33% on the day, with a bearish technical signal despite bullish moving averages. The stock shows strong fundamentals with a 72.7% net income margin in 2025 and consistent earnings beats. Recent news highlights robust Q1 2026 results and a 4% dividend yield, though some analysts express caution on valuation. Cash flow trends indicate increased capital expenditures, with net cash flow turning negative in 2025.
Outlook remains mixed: strong leasing activity and raised FFO guidance support upside, but high debt levels and e-commerce risks weigh on sentiment. Analysts are predominantly neutral with a $214.40 consensus target, slightly below current price. Investors should balance income appeal against valuation concerns and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
